ELISA in PK and ADA Testing for Macromolecular Drugs

Biopharmaceutical advancements over recent years have propelled macromolecular drugs like monoclonal antibodies (mAbs) into a central position within the industry. Precise and sensitive detection methods that are also cost-effective are crucial to optimize treatment plans and assess drug levels and immunogenic responses. ELISA distinguishes itself in drug testing because of its straightforward operation and combined benefits of high sensitivity and cost efficiency which establish it as the best method for PK analysis and ADA detection in macromolecular drugs.

Figure 1. Modes of Action of Monoclonal Antibodies (Source: Dostalek M, et al. 2013)

1. ELISA for Macromolecular Drug PK Analysis

Principle:

ELISA utilizes antigen-antibody binding specificity by fixing either the capture antibody or antigen onto a solid-phase platform which commonly includes microplates built from rigid materials like polystyrene, polyethylene, or polypropylene. The detection antibody which is conjugated with an enzyme gets added once the target drug within the sample connects with the capture molecule. When researchers add suitable substrate to the enzyme, the enzyme generates a reaction that creates a colorimetric signal detectable at approximately 450 nm which allows precise drug measurement across a broad dynamic range. This technique yields essential information about how the drug moves through the body from absorption to excretion.

Comparison with Other Methods:

LC-MS/MS: Though LC-MS/MS provides exceptional sensitivity and selectivity for small molecule quantification it faces limitations in macromolecular drug analysis because of large molecular weight and structural complexity which together with matrix interferences require extensive sample preparation. ELISA provides a simpler and cheaper solution which makes it perfect for regular PK studies involving macromolecular drugs.
Chemiluminescence Immunoassay: While Chemiluminescence Immunoassay offers even higher sensitivity by utilizing chemiluminescent reactions, its higher equipment costs and operational complexity restrict its use mainly to clinical diagnostics. For large-scale PK studies and therapeutic drug monitoring (TDM), ELISA retains a significant advantage due to its high throughput and cost-effectiveness.

2. ELISA for Anti-Drug Antibody (ADA) Detection

Principle:

ADA commonly develop in patients receiving macromolecular therapies such as monoclonal antibodies which represents a crucial immune response that affects treatment effectiveness and patient safety. The standard ELISA method for ADA detection uses a bridging assay technique in which the target drug or its unique antibody is pre-coated onto a solid phase platform. ADAs from patient samples create bivalent bridges with the drug after addition and a detection antibody linked with an enzyme measures the resulting immune complexes.

Figure 2. Detection of Anti-Drug Antibodies (ADAs) Using Indirect Capture ELISA in a Mouse Model (Source: Ubah OC, et al. 2020)

Comparison with Other Methods:

Luminex Technology: Using bead-based flow cytometry, Luminex can simultaneously detect multiple targets and is suitable for high-throughput, multiplex assays. However, due to its mature platform and lower cost, ELISA remains the mainstream choice for ADA monitoring.
Western Blot: Although Western blotting can provide molecular weight information for proteins, its labor-intensive process and difficulty in quantification render it unsuitable for large-scale ADA screening. ELISA, by comparison, is more convenient and ideal for quantitative detection of ADA levels.

Optimization Steps for ELISA Detection of ADA

Specific Step	Description
Sample Preparation
Serum/Plasma Collection	Collect blood using anticoagulant tubes, and try to avoid drug interference. When drug concentration is high, samples can be collected before drug administration to reduce drug interference.
Drug Interference Handling	For samples containing drug-ADA complexes, perform acid dissociation treatment (e.g., by adding acid or using an antigen binding test (ABT)) to separate drug-antibody complexes, reducing the drug's impact on ADA detection.
Storage	Samples should be stored at -80°C to maintain stability and avoid ADA level changes caused by temperature fluctuations.
Plate Coating
Coating Conditions	Coat the biopharmaceutical drug onto the surface of a 96-well plate. The coating concentration of the drug should be optimized to ensure sufficient capture capacity, usually by incubating overnight at 4°C to maximize the coating effect.
Coating Concentration	The concentration of the coating drug needs to be optimized based on the drug's affinity and the strength of the antibody response.
Blocking
Choice of Blocking Buffer	Use 1–5% bovine serum albumin (BSA) or casein to block the wells, reducing non-specific binding. The blocking buffer should be incubated at room temperature for 1 hour to ensure effective blocking.
Blocking Time and Temperature	Ensure that the time and temperature are sufficient to help reduce background noise.
Addition of Samples and Standards
Sample Dilution	Add diluted serum or plasma samples, as well as standards or controls. For ADA detection, a positive control should be added.
Incubation Conditions	Incubate at 37°C for 1–2 hours to improve the binding efficiency of ADA with the drug. This step is crucial for enhancing sensitivity.
Antibody Addition
Choice of Detection Antibody	Based on the type of target ADA, add the appropriate enzyme-labeled anti-human IgG (or other immunoglobulin subtypes, such as IgM/IgE). The detection of ADA should target both free ADA and drug-bound ADA.
Incubation Conditions	Incubate at room temperature for 1 hour to ensure the detection antibody binds with the ADA.
Enzyme-Substrate Reaction
Choice of Colorimetric Substrate	Add TMB (tetramethylbenzidine) or another colorimetric substrate, and incubate in the dark for 10–30 minutes. The enzyme reaction product will reflect the presence and level of ADA through a color change.
Optimization of Color Development Time	The time for the colorimetric reaction should be adjusted according to the experimental conditions to avoid signal saturation due to overreaction.
Reaction Termination and Reading
Termination of Reaction	Use sulfuric acid or another stop solution to halt the enzyme reaction.
Absorbance Measurement	Read the absorbance (OD value) at 450 nm, and calculate the ADA concentration based on the standard curve.

3. Key Considerations in ADA Testing:

Managing Drug Interference: Drug-ADA complexes can lead to an underestimation of free ADA levels. When drug concentrations rise, acid dissociation treatment along with antigen-binding tests (ABT) serve as powerful methods to minimize interference. The employment of competitive ELISA or bridging ELISA methods can improve specificity and sensitivity which helps in decreasing false-positive results.

ADA Subtype Detection: The standard ELISA approach focuses on IgG-type ADAs but occasionally requires analysis of different immunoglobulin subtypes to completely understand the ADA profile and its impact. Bridging ELISA is particularly effective in detecting bivalent ADAs, offering more precise quantitative analysis.

Sensitivity and Specificity: False positives in ADA detection can occur due to the presence of rheumatoid factor (RF) or heterophilic antibodies. Employing highly sensitive ELISA techniques like sandwich or bridging ELISA leads to improved accuracy. To achieve consistent results across different batches and laboratories ELISA protocols require strict standardization due to inherent variability.

Figure 3. Drug Tolerance of Bridging ELISA vs. RIA in Adalimumab-Treated RA Patients (Source: Jani M, et al. 2016)

ELISA achieves accurate PK parameter estimation through rigorous quality control measures and optimized solid-phase materials, enzyme-substrate systems, and incubation conditions while efficiently detecting ADA formation. Integrating acid dissociation treatment alongside ABT and standardized protocols will be essential to achieve better ADA detection accuracy in future advancements. Creative Diagnostics supplies high-quality ELISA kits that are tailored for PK and ADA analysis of macromolecular drugs enabling reliable and fast solutions which advance pharmacokinetic studies and immunogenicity assessments.

References

Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, Pharmacodynamics, and Physiologically-Based Pharmacokinetic Modeling of Monoclonal Antibodies. Clin Pharmacokinet. 2013;52(2):83-124.
Ubah OC, Porter AJ, Barelle CJ. In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA. J Immunol Res. 2020;7283239:1-14.
Jani M, Isaacs JD, Morgan AW, et al. Detection of Anti-Drug Antibodies Using a Bridging ELISA Compared with Radioimmunoassay in Adalimumab-Treated Rheumatoid Arthritis Patients with Random Drug Levels. Rheumatology. 2016;55(11):2050-2055.

ADA ELISA Kits

Target	Cat. No.	Product Name	Size	Species	Application	Detection Sample
Exendin-4	DEIABL206	Exendin-4 ADA ELISA kit	96T	Human	Quantitative	Serum, plasma	Inquiry
TNF	DEIA068J	TNF α-Blocker ADA, Antibodies against infliximab ELISA Kit	96T	Human	Qualitative	serum, EDTA plasma	Inquiry
	DEIA069J	TNF α-Blocker ADA, Total Antibodies against infliximab ELISA Kit	96T	Human	Qualitative	serum, EDTA plasma	Inquiry
	DEIA018J	TNF α-Blocker ADA, Antibodies against etanercept ELISA Kit	96T	Human	Qualitative	EDTA plasma, serum	Inquiry
	DEIA019J	TNF α-Blocker ADA, Antibodies against infliximab ELISA Kit	96T	Human	Qualitative	EDTA plasma, serum	Inquiry
	DEIA020J	TNF α-Blocker ADA, Total Antibodies against infliximab ELISA Kit	96T	Human	Qualitative	EDTA plasma, serum	Inquiry

PK ELISA Kits

Target	Cat. No.	Product Name	Size	Species	Application	Detection Sample
Semaglutide	DEIASL092	Semaglutide ELISA Kit	96T	NA	Quantitative	Serum, plasma	Inquiry
Ramucirumab	DEIAZ0009	Anti-Ramucirumab ELISA Kit	96T	Human	Qualitative	Serum, plasma	Inquiry
Filgrastim	DEIABL228	Filgrastim Elisa kit	2 x 96T	Human	Quantitative	Serum, plasma	Inquiry
Liraglutide	DEIA-XYZ95	Liraglutide High Sensitivity Elisa Kit	96T	NA	Quantitative	Serum, plasma	Inquiry
MMAE	DEIABL314	Intact MMAE ADC ELISA Kit	96T	Human	Quantitative	Serum, plasma	Inquiry
DM1	DEIABL311	DM1 ADC ELISA Kit	96T	Human	Quantitative	Serum, plasma	Inquiry
SN38	DEIABL316	SN38 ADC ELISA Kit	96T	Human	Quantitative	Serum, plasma	Inquiry
Eculizumab	DEIAZ0063	Eculizumab ELISA kit	96T	NA	Quantitative	Serum, plasma, cell culture samples	Inquiry